ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.96
0.71%
US Tech 100
20,762.73
1.73%
S&P 500
5,942.47
1.26%
US Dollar vs CAD
1.44457
0.00%
Bitcoin
98,298.45
0.09%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Brazil
  5. BOV

  6. Gafisa S.A. (GFSA3) Share Price

Gafisa S.A.

Gafisa S.A. (GFSA3)

BOV
1.22
0.06
(5.17%)
Closed January 05 2:55PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
1.19
Bid
1.17
Ask
1.20
Volume
4,380,600
1.17 Day's Range 1.24
1.09 52 Week Range 16.39
Market Cap
106.436M
Previous Close
1.16
Open
1.17
Last Trade
3000
@
1.19
Last Trade Time
Financial Volume
R$ 5,261,101
VWAP
1.201
Average Volume (3m)
5,223,724
Shares Outstanding
89,442,291
Dividend Yield
-
PE Ratio
-0.54
Earnings Per Share (EPS)
-2.18
Revenue
1.34B
Net Profit
-195.31M

About Gafisa S.A.

Sector
Real Estate Agents & Mgrs
Industry
Real Estate Agents & Mgrs
Website
www.gafisa.com.br
Headquarters
Sao Paulo, Sao Paulo, Bra
Founded
-
Gafisa S.A. is listed in the Real Estate Agents & Mgrs sector of the Brazil Bovespa Exchange with ticker GFSA3. The last closing price for GAFISA ON was R$1.16. Over the last year, GAFISA ON shares have traded in a share price range of R$ 1.09 to R$ 16.39.

GAFISA ON currently has 89,442,291 shares outstanding. The market capitalization of GAFISA ON is R$103.75 million. GAFISA ON has a price to earnings ratio (PE ratio) of -0.54.

Ask ADVFN Intelligence (AI)

GFSA3 Latest News

More News
No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.087.207207207211.111.241.0928702671.16342721CS
4-0.25-17.36111111111.441.451.0945037691.22941417CS
12-0.71-37.36842105261.921.0952237241.50214493CS
26-2.05-63.27160493833.244.141.0942946722.16458299CS
52-8.26-87.40740740749.4516.391.0943170935.27039571CS
156-0.83-41.08910891092.0233.971.0246201925.1788414CS
260-8.34-87.51311647439.5333.971.0254878854.91264521CS

GFSA3 - Frequently Asked Questions (FAQ)

What is the current GAFISA ON share price?
The current share price of GAFISA ON is R$ 1.19
How many GAFISA ON shares are in issue?
GAFISA ON has 89,442,291 shares in issue
What is the market cap of GAFISA ON?
The market capitalisation of GAFISA ON is BRL 103.75M
What is the 1 year trading range for GAFISA ON share price?
GAFISA ON has traded in the range of R$ 1.09 to R$ 16.39 during the past year
What is the PE ratio of GAFISA ON?
The price to earnings ratio of GAFISA ON is -0.54
What is the cash to sales ratio of GAFISA ON?
The cash to sales ratio of GAFISA ON is 0.08
What is the reporting currency for GAFISA ON?
GAFISA ON reports financial results in BRL
What is the latest annual turnover for GAFISA ON?
The latest annual turnover of GAFISA ON is BRL 1.34B
What is the latest annual profit for GAFISA ON?
The latest annual profit of GAFISA ON is BRL -195.31M
What is the registered address of GAFISA ON?
The registered address for GAFISA ON is AV. PRESIDENTE JUSCELINO KUBITSCHEK N�� 1830, SAO PAULO, SAO PAULO, 05425-070
What is the GAFISA ON website address?
The website address for GAFISA ON is www.gafisa.com.br
Which industry sector does GAFISA ON operate in?
GAFISA ON operates in the REAL ESTATE AGENTS & MGRS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AZEV11Azevedo Travassos Sa
R$ 0.28
(47.37%)
42.2k
JFEN3Joao Fortes Engenharia Sa
R$ 2.71
(18.34%)
239.56k
VLID3Valid Solucoes E SV De SEG EM Meios
R$ 25.00
(16.28%)
749.17k
AERI3Aeris Industria E ComerciodeEquipamentos paraGeracaodeEnergiaS.A
R$ 7.94
(13.43%)
935.03k
PINE3Banco Pine SA
R$ 4.94
(12.02%)
13.1k
COCE11Cia Energetica Ceara Coelce
R$ 0.62
(-35.42%)
10.7k
RADL3QRaia Drogasil SA
R$ 21.46
(-11.07%)
138k
AALR3Allianca Saude e Participacoes S.A.
R$ 7.27
(-9.13%)
67.2k
OFSA3Ourofino S.A
R$ 16.01
(-8.83%)
6.9k
FICT3Fictor Alimentos S.A.
R$ 3.03
(-8.18%)
39.3k
POMO4Marcopolo Sa
R$ 7.35
(-4.05%)
24.33M
CMIN3CSN Mineracao S.A
R$ 4.88
(-3.17%)
19.02M
ITUB4Itau Unibanco Holding SA
R$ 29.82
(-2.45%)
14.89M
HAPV3Hapvida Participacoes Investimento SA
R$ 2.10
(-3.23%)
13.92M
PETR3Petroleo Brasileiro S.A. Petrobras
R$ 40.38
(-0.35%)
12.65M

Discussion

View Full Feed
sand sand 5 minutes ago
Thank you Ducci for all your sharing and insights extremely helpful. I'm slowly diligently getting there rewiring the brain and focusing on what shows the moves. Much continued success this week. Thank you again.
SPY
mining101 mining101 6 minutes ago
Moving hard soon 
EFSH
mining101 mining101 7 minutes ago
Superb
MEGL
benz280c benz280c 14 minutes ago
Speak louder and maybe you will convince somebody that this is how you really feel. No need to be insecure around your fellow investors.
GDVM
rx7171 rx7171 21 minutes ago
In addition MABs are approved for only a limited portion of the AD population, whereas Blarcamasine appears to be effective in 70-80% of the ITT population with its strongest efficacy in the 70% with wild type Sigma-1.
AVXL
TheHound TheHound 22 minutes ago
Learn how to use the bull market support band with that chart and you’ll have a powerful tool under your belt!
XRPUSD
Investor2014 Investor2014 25 minutes ago
When I say that the totality of information is what Anavex rely on it does take into account the pretty ineffective SOC, associated risks and inconveniences for patients.

Still any drug regulatory process must and should look carefully at the data to ensure that neither type one or tw
AVXL
nowwhat2 nowwhat2 30 minutes ago
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
BTCUSD
rx7171 rx7171 31 minutes ago
Yes that spike to $23 in June of 2021 was driven entirely by the excellent Phase II data for PDD.

Yet now after completing the AD 2b/3 trial and having an EMA MAA accepted for evaluation the share price is barely half that number!

I understand the company being very ca
PDD
sunspotter sunspotter 35 minutes ago
Black Cat Moan was one of my favorites back in the day:

https://youtu.be/cxN-frB1UbI?si=Ph6XMC3omR0rRlmR

Edit: auto correct changed Moan to Moana. The cultural prevalence of Disney.
Investor2014 Investor2014 38 minutes ago
The ex-biotech executive is back in the Rett trap posting mode - hope it goes better with the biased approach this time.

Listing all the site PI’s is not world class peer review WGT confirmation.
AVXL
nowwhat2 nowwhat2 39 minutes ago
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
sunspotter sunspotter 41 minutes ago
I rather think you missed the point. It’s not that higher doses of GALT’s drug are toxic, it’s that they are ineffective.

Given the purported mechanism, that almost certainly means lower doses are too, and that the implication that the lower dose worked is merely an artefact.
GALT
nowwhat2 nowwhat2 44 minutes ago
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
XRPUSD
CrossFireTrader CrossFireTrader 47 minutes ago
I try to avoid Krispy Kreme's af all costs. Thanks for your insight...
GDVM
skitahoe skitahoe 47 minutes ago
Dstock, you may be very right about the data from compassionate use being included, but if it is, I would think that the protocols used on every one of those patients would need to be included as none are specifically on the trial protocol. It's essentially anecdotal evidence, but it could all add
NWBO
Pickme2 Pickme2 48 minutes ago
Stop wasting our time with your ongoing Manipulated nonsense.... Just read the S-1 
Filed with the sec.... 


ATMH
georgejjl georgejjl 49 minutes ago
The MABs are no where near being the standard of care for treating Alzheimer’s patients.
AVXL
benz280c benz280c 51 minutes ago
Phone died when responding to that. In summary, I think the 24/7 is multi-pronged. It is necessary for the kind of business that Veemost is and will be, which aligns it and will help it qualify for Gold. I do not recall it expressly said that Gold was reached and turned down. Not saying that didn't
GDVM
Sheepdog Sheepdog 1 hour ago
Really? So you think the SEC is going to start arresting OTC Scammers and Pump/Dumpers? I hope so...about time.
GCAN
Hummingbird2 Hummingbird2 1 hour ago
$GTII ~ Just listen in the first 5 mins about $GTII 🛫 after March? https://www.youtube.com/watch?v=Ag2f2rDlq5g
GTII
Jane1999 Jane1999 1 hour ago
Here the CEO : https://www.wsj.com/market-data/quotes/CA/XCNQ/TWOH/company-people/executive-profile/149699
TWOH
Curious Bystander Curious Bystander 1 hour ago
The Expert Market was set up by the SEC for several very specific reasons. But you could generally say that a security lands in that market when a company is either UNABLE or UNWILLING to file certain SEC-required forms.

UNABLE or UNWILLING. Hmmmm…..I wonder which category Quantum
FLCX

Your Recent History

BOV
GFSA3
GAFISA ON
HITB
SCBTC
Siacoin
TG
A2R3N6
Caixabank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads